The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 21.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 79%. Our forward projection puts the odds of a 10% gain over the next month near 16%.
Bio Green Med Solution Inc BGMS
Outside both standardsAn entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Bio Green Med Solution, Inc.
read at $0.95
Bio Green Med Solution Inc holds its Accumulation at $0.95.
- PHPhase · the trend structure carries the Accumulation label
- INInsiders · no filings inside 60 days, left as found
- POPositioning · no disclosures inside 60 days, left as found
- OPOptions · no verdict drawn today, left as found
- SCScreen · does not pass the values gate
- edge confirmed
- edge broken
- edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
The investor read · the season, not the day
| Phase | Accumulation |
| Quantitative state | Consolidating, no directional conviction, held for 79 days |
| Price | $0.95 |
| Valuation | 0.19 trailing · N/A forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | -0.37 |
The business, in plain words · what the numbers mean
| Trailing P/E | 0.2x very cheap relative to earnings |
| Profit margin | -204.2% currently unprofitable |
| Return on equity | 20.6% an exceptional return on shareholder capital |
| Current ratio | 7.06 comfortably covers its short-term bills |
| Beta | -0.37 barely tracks the market's swings |
| Market cap | $5M |
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; its business and earnings are exposed to Malaysia and to currency swings; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Related securities · others in BGMS's space worth a look
Screened names in the same industry · explore each on its own page.
The trader read · the latest dated commentary
The dated journal · newest first, never edited
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 79%. Our forward projection puts the odds of a 10% gain over the next month near 16%.
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
What holding actually paid · price plus dividends
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $0.90 | -1.1% | · | $989 | -1.1% |
| 2 months | $1.01 | -11.9% | · | $881 | -11.9% |
| 3 months | $0.95 | -6.3% | · | $937 | -6.3% |
| 6 months | $1.50 | -40.7% | · | $593 | -40.7% |
| 1 year | $4.20 | -78.8% | · | $212 | -78.8% |
| 2 years | $217.82 | -99.6% | $36.00 | $169 | -83.1% |
| 3 years | $1,164.41 | -99.9% | $36.00 | $32 | -96.8% |
| 5 years | $12,200.27 | -100.0% | $36.00 | $3 | -99.7% |
Historical returns from market close data. Past performance does not guarantee future results.